Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens

Abstract

The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods.

1 . An antigen panel for identifying immunoreactivity associated with a premalignant or malignant prostate, the panel comprising a plurality of antigens, wherein the antigens of the panel are selected based on their capacity in aggregate to elicit an immune response in at least about 33% of individuals with prostatitis or prostate cancer. 
     
     
         2 . The panel of  claim 1 , wherein the plurality of antigens are selected from the group consisting of PRO1, PRO2, PRO3, PRO4, PRO5, PRO6, PRO7, PRO8, PRO9, PRO10, PRO11, PRO12, PRO13, PRO14, PRO15, PRO16, PRO17, PRO18, PRO19, PRO20, PRO21, PRO22, PRO23, PRO24, PRO25, PRO26, PRO27, PRO28, PRO29, PRO30, PRO31, PRO32, PRO33, PRO34, PRO35, PRO36, PRO37, PRO38, PRO39, PRO40, PRO41, CTA1, CTA2, CTA3, CTA4, CTA5, CTA6, CTA7, CTA8, CTA9, CTA10, CTA11, CTA12, CTA13, CTA14, CTA15, CTA16, CTA17, CTA18, CTA19, CTA20, CTA21, CTA22, CTA23, CTA24, CTA25, CTA26, CTA27, CTA28, CTA29, PCA1, PCA2, PCA3, PCA4, PCA5, PCA6, PCA7, PCA8, PCA9, PCA10, PCA11, PCA12, PCA13, PCA14, PCA15, PCA16, PCA17, PCA18, PCA19, PCA20, PCA21, PCA22, PCA23, PCA24, PCA25, PCA26, PCA27, PCA28, PCA29, PCA30, ADT1, ADT2, ADT3, ADT4, ADT5, ADT6, ADT7, ADT8, ADT9, ADT10, ADT11, ADT12, ADT13, ADT14, ADT15, ADT16, ADT17, ADT18, ADT19, ADT20, ADT21, ADT22, ADT23, ADT24, ADT25, ADT26, ADT27, and ADT28. 
     
     
         3 . The panel of  claim 1 , wherein each antigen has a positive likelihood ratio of at least 4. 
     
     
         4 . The panel of  claim 1 , wherein the plurality of antigens comprise ADT14, CTA3, CTA23, PCA6, PCA8, PCA10, PCA16, PRO5, PRO10, PRO12, PRO17, PRO18, PRO19, PRO20, PRO24, PRO25, PRO35, CTA27, PCA21, PRO40, PCA2, PRO34, and PRO32. 
     
     
         5 . The panel of  claim 1 , wherein at least three of the antigens in the panel elicit an immune response in at least about 9% of individuals with prostatitis or prostate cancer. 
     
     
         5 . A method for identifying a human or non-human animal as a candidate for prostate cancer examination comprising the steps of:
 (a) contacting a sample obtained from the human or non-human animal with the panel of  claim 1  under conditions suitable for immunocomplex formation, wherein the sample comprises at least one antibody; and   (b) identifying the human or non-human animal as a candidate if at least one immunocomplex forms between the at least one antibody and at least one antigen of the panel.   
     
     
         6 . The method of  claim 5 , wherein the sample is a bodily fluid. 
     
     
         7 . The method of  claim 5 , wherein the sample is serum. 
     
     
         8 . The method of  claim 5 , wherein at least three immunocomplexes between antibodies in the sample and antigens of the panel are detected. 
     
     
         9 . A kit comprising an antibody detection panel and a carrier or medium, wherein the panel is for identifying immunoreactivity associated with a premalignant or malignant prostate, the panel comprising a plurality of antigens, wherein the antigens of the panel are selected based on their capacity in aggregate to elicit an immune response in at least about 33% of individuals with prostatitis or prostate cancer. 
     
     
         10 . The kit of  claim 9 , wherein the plurality of antigens are selected from the group consisting of PRO1, PRO2, PRO3, PRO4, PRO5, PRO6, PRO7, PRO8, PRO9, PRO10, PRO11, PRO12, PRO13, PRO14, PRO15, PRO16, PRO17, PRO18, PRO19, PRO20, PRO21, PRO22, PRO23, PRO24, PRO25, PRO26, PRO27, PRO28, PRO29, PRO30, PRO31, PRO32, PRO33, PRO34, PRO35, PRO36, PRO37, PRO38, PRO39, PRO40, PRO41, CTA1, CTA2, CTA3, CTA4, CTA5, CTA6, CTA7, CTA8, CTA9, CTA10, CTA11, CTA12, CTA13, CTA14, CTA15, CTA16, CTA17, CTA18, CTA19, CTA20, CTA21, CTA22, CTA23, CTA24, CTA25, CTA26, CTA27, CTA28, CTA29, PCA1, PCA2, PCA3, PCA4, PCA5, PCA6, PCA7, PCA8, PCA9, PCA10, PCA11, PCA12, PCA13, PCA14, PCA15, PCA16, PCA17, PCA18, PCA19, PCA20, PCA21, PCA22, PCA23, PCA24, PCA25, PCA26, PCA27, PCA28, PCA29, PCA30, ADT1, ADT2, ADT3, ADT4, ADT5, ADT6, ADT7, ADT8, ADT9, ADT10, ADT11, ADT12, ADT13, ADT14, ADT15, ADT16, ADT17, ADT18, ADT19, ADT20, ADT21, ADT22, ADT23, ADT24, ADT25, ADT26, ADT27, and ADT28. 
     
     
         11 . The kit of  claim 9 , wherein each antigen has a positive likelihood ratio of at least 4. 
     
     
         12 . The kit of  claim 9 , wherein the plurality of antigens comprise ADT14, CTA3, CTA23, PCA6, PCA8, PCA10, PCA16, PRO5, PRO10, PRO12, PRO17, PRO18, PRO19, PRO20, PRO24, PRO25, PRO35, CTA27, PCA21, PRO40, PCA2, PRO34, and PRO32. 
     
     
         13 . The kit of  claim 9 , wherein at least three of the antigens in the panel elicit an immune response in at least about 9% of individuals with prostatitis or prostate cancer.